Search
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigationalDefactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersDoravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. Doravirine is available by itself or as a combination product of doravirine (10...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor–directed
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalOmaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mit...
Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesTradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigationalTradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors.
Categories: Substance P/Neurokinin-1 Receptor Antagonist, P-glycoprotein substratesZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inh...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSecnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigationalSecnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-l...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: SECNIDAZOL 500 MG POLVO P RECONSTRUIR, SECNIDAZOL 750 MG POLVO P. RECOSTRUIRGrapiprant
go.drugbank.com/drugs/DB12836InvestigationalVet approvedThese molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin receptor antagonists.
Categories: P-glycoprotein substratesTazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigationalTazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA app...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates